Background: In a major clinical trial, caspofungin was as efficacious as liposomal amphotericin B (LAmB) for empirical therapy in febrile neutropenia. The current study sought to evaluate the economic impact of caspofungin as compared with LAmB for febrile neutropenia in Australia.
Introduction
The concept of empirical use of antifungal agents is recognized as the standard of care for patients with febrile neutropenia. 1 A variety of agents have been employed for empirical use. Ideally, an antifungal for empirical use should have demonstrated activity against the most common causative fungi for infections, namely Candida and Aspergillus species. In a double-blind, randomized, multicentre clinical trial by Walsh et al., 5 comparing caspofungin with LAmB for empirical therapy in febrile neutropenic patients, caspofungin was shown to be non-inferior to LAmB. The authors concluded that caspofungin is a suitable alternative to LAmB for empirical treatment. However, given the differential costs of these agents, related health economic data would be critical to establish the role of caspofungin as the latest addition to the empirical antifungal armamentarium. No overall economic evaluation has been performed yet on empirical caspofungin.
The objective of the current study was to investigate the pharmacoeconomics of caspofungin as compared with standard care (i.e. LAmB) 6, 7 for empirical antifungal therapy of febrile neutropenia in Australia.
Materials and methods
The modelling in the current study was based on data extrapolated from the randomized trial by Walsh et al. 5 on empirical therapy in febrile neutropenia. In the trial, 1095 patients were randomly assigned to receive either caspofungin or LAmB. Successful therapy was determined by a five composite endpoint, comprising absence of breakthrough fungal infection, survival for 7 days beyond the therapy completion, no premature discontinuation of therapy because of related side effects or lack of efficacy, resolution of fever during the period of neutropenia and successful treatment for any baseline fungal infection.
Perspective
The economic analysis was undertaken from the perspective of the Australian hospital system. The analysis included direct medical costs related to febrile neutropenia. These included costs of diagnostic and monitoring tests, medical therapy, concomitant medications, hospitalization and duration of therapy. Indirect medical costs related to other underlying diseases were not included.
Model structure
A decision analytic model 8 was constructed to capture the downstream consequences of empirical antifungal therapy with each agent (Figure 1 ).
The model included eight possible treatment pathways depending on whether the initial treatment was successful, and on the reasons for failures. Patients with febrile neutropenia were initially assigned to one of two pathways depending on whether they had baseline fungal infections. Patients without baseline infection continued therapy until success, or failure because of death, breakthrough fungal infections, premature discontinuations or persistent fever. Patients with baseline infection continued therapy until success, or failure because of death or persistent baseline infection.
Patients who failed to respond to initial therapy for reasons other than death were switched to any licensed antifungal therapy. No specifications were made regarding when therapy ended. All patients were followed until death or successful therapy. Success was the result of either initial therapy or alternative therapy.
Model inputs
Input data derived from the trial 5 included clinical outcome rate, morbidity and mortality, duration of initial therapy and cause of treatment failure. Clinical outcomes and their probabilities are summarized in Table 1 .
An independent expert panel was convened comprising four clinicians from Australia with clinical expertise in systemic fungal therapy and specialist knowledge in oncology, haematology and infectious diseases. The panel provided a consensus view on required data that were not available from the literature. These included concomitant antibiotics, screening and monitoring tests and intensive care unit (ICU) management that relates to fungal infections. The panel also advised on alternative antifungal therapies used after initial therapy discontinuation. The choice of alternative therapy was dependent on the reason for treatment discontinuation, 5 which included, where breakthrough infections and baseline infections occurred, the site of infection and the type of causative fungi. The expert panel validated the decision tree in the current model.
Based on the trial, patients on caspofungin received 70 mg on day 1, followed by a daily dose of 50 mg. LAmB was administered intravenously at 3 mg/kg/day throughout the treatment duration. The mean duration of caspofungin administration was 13 days. For LAmB, the mean duration of therapy was 12.5 days. Baseline fungal infections were those present within 48 h of therapy initiation. Breakthrough fungal infections were those diagnosed after 48 h of therapy. For the purpose of this study, patients with premature discontinuations were further classified according to premature discontinuations because of severe toxicity (i.e. infusion-related reaction, hepatotoxicity and nephrotoxicity) and those due to lack of efficacy against suspected fungal infection or persistent fever. 
Economics of empirical caspofungin

Data provided by expert panel
Filgrastim [granulocyte-colony stimulating factor (G-CSF)], piperacillin/tazobactam and vancomycin were concomitantly given to patients. Patient monitoring tests comprised a daily complete blood count, as well as renal and liver function tests. For diagnostic tests, a chest X-ray was done at onset of therapy and then three times weekly. Patients received a computed tomography (CT) scan 3 days after commencing antifungal therapy, with 40% of patients receiving a second follow-up scan. Blood and non-blood microbiological cultures (i.e. sputum, biopsy, diarrhoea and urine) were performed two to three times a week. Based on the panel's advice, it was assumed that 7.5% of patients spent 5 days in the ICU, where patients received a bronchoscopy, an additional CT scan, thrice-daily tests of electrolytes and daily monitoring of blood and non-blood microbiological cultures. Antibiotics and G-CSF, screening and monitoring tests and ICU management were not affected by the type of empirical antifungal agent and, therefore, their frequency and nature were the same during both therapies. As reported by Walsh et al., 5 27 patients receiving caspofungin prematurely ceased treatment because of side effects. The expert panel felt that 21 of these discontinuations would be due to infusion-related reactions. Three patients had nephrotoxicity and three had hepatotoxicity. Out of the 44 patients who discontinued LAmB prematurely because of side effects, 5 9 had infusion-related reactions, 31 had nephrotoxicity and four had hepatotoxicity. Patients who had baseline infections and failed therapy survived with persistent baseline infections. The antifungal alternatives given after the failures of each of the therapies were as shown in Table 2 .
Other study assumptions
The assumptions made with respect to determining costs in the present study were as follows:
(i) Patients did not incur any out-of-pocket costs, and were covered by Medicare (Australia's public health insurance scheme). (ii) If patients switched initial therapy after initial failure, the subsequent alternative therapy was successful. (iii) Any alternative therapy was assumed to have a duration similar to that of the discontinued initial therapy.
All assumptions were validated by the expert panel.
Cost calculations
This model was used to generate a weighted average cost per patient. This was the sum-product of the eight-treatment-outcome costs and their respective probabilities. The cost of the initial therapy was the cost of a complete course of caspofungin or LAmB before changing to alternatives. The cost of the alternative therapy was the cost of a complete course of the alternative agent. The cost of each failure pathway, except for death, was the cost of initial and alternative therapies added to the cost of resources consumed. The cost per successfully treated or deceased patient was calculated as a proportion of both the cost of a complete course of caspofungin or LAmB and the cost of resources used.
Regarding medication doses, all patients were assumed to have an average body weight of 76.05 kg, based on the latest available data from the Australian Bureau of Statistics. 9 No average patient body weight was reported in the Walsh et al. 5 study. Doses for all medications (except posaconazole) were rounded to the nearest vial size. Patients on posaconazole were permitted to share the same posaconazole bottle, as is routine hospital practice in Australia.
Costs were calculated in Australian dollars (AU$) for the financial year 2008-09, and no discounting was applied given the short time-frame of analysis.
Medication costs used were the drug wholesale prices paid by Australian public hospitals, as per Health Purchasing Victoria tender (2007-09). 10 Hospitalization costs were obtained from published records associated with Australian Refined Diagnosis-Related Groups (2006-07). 11 Hospitalization costs used were the average total costs associated with febrile neutropenia, and included the cost of intensive care management. Hospitalization costs were adjusted for the financial year 2008-09 as per the Australian Consumer Price Index (2008). 12 All other resource costs involved in the study were obtained from the Australian Medicare Benefits Schedule Book (2009). 13 The cost inputs used in the model are summarized in Table 3 .
Sensitivity analyses
Deterministic and probabilistic sensitivity tests were produced by modifications of the baseline values of several key variables and assumptions, in relation to costs and probabilities, to evaluate the robustness of the study conclusion. Baseline values were substituted by the highest and lowest values within a reasonable range of values. Where a substitution changes the study conclusion, more values within the range replaced the baseline value. This was repeated until the exact variable value (or range of values) that changes the study outcome was identified.
The effects of variations in the duration and cost of hospital stay and the caspofungin and LAmB prices were investigated. The impact of estimations made by the expert panel was also evaluated. These were related to alternative medications used, ICU duration, antibiotic and G-CSF use and screening and monitoring tests. Key variables, and the ranges over which they were varied, are shown in Table 4 . The model's sensitivity to the probability of patient distribution in the decision tree was investigated by switching the probability data between the caspofungin and LAmB arms, and by applying the probability data in the LAmB arm to the caspofungin arm and vice versa. Another scenario analysed was replacing the probability of patient distribution in the LAmB arm with that reported in a similar study comparing empirical LAmB with empirical voriconazole. of a model input, are added into the model. 15 The model is run for each simulated input, resulting in a range of outputs characterizing the output uncertainty. An accurate probabilistic sensitivity analysis typically requires 1000 or more model runs. 15 The clinical outcomes that affected the overall drug cost the most were also determined. One-way sensitivity analysis was performed with an assumed uncertainty of 10% for the probabilities of breakthrough fungal infection, premature discontinuation and persistent fever. A 5% uncertainty range was applied for all other probabilities in the model. Corresponding costs were calculated, and a distribution of 'cost saving' was obtained by executing 10000 iterations of the Monte Carlo simulation. The input variables and their uncertainty distributions are shown in Table 5 .
Results
Cost of empirical therapy
Caspofungin had an economic advantage over LAmB in the order of AU$7245 (12.6%). The proportions and costs for each pathway in the decision tree are shown in Table 6 . For both antifungals, persistent fever was the main contributing clinical outcome to therapeutic costs. Main components, and their contribution, in the overall costs of caspofungin and LAmB are demonstrated in Figure 2 .
Higher probability of success and lower probability of death were associated with caspofungin (34.17% and 7.37%, respectively) versus LAmB (33.58% and 10.76%, respectively) ( Table 1 ). The costs of success and survival per patient with caspofungin (AU$147097 and AU$50304, respectively) were lower than those with LAmB (AU$171266 and AU$57574, respectively).
Sensitivity analyses
Sensitivity analyses demonstrated that the baseline cost difference was most sensitive to the duration of either of the antifungals. LAmB had a lower overall cost when the duration of caspofungin therapy increased from 13 to .14.9 days, or when the LAmB therapy was reduced in duration from 12.5 to ,10.9 days. The cost per day was higher with LAmB (AU$4377 versus AU$3742).
The model was insensitive to changes in drug acquisition costs. LAmB had the economic advantage when its price decreased from AU$295.00 to AU$174.40 per vial. A 2-fold increase in the 70 mg caspofungin price did not affect the cost savings. Increasing the price of 50 mg caspofungin alone or the price of both 70 and 50 mg caspofungin from AU$700 to AU$1330 per vial was needed for LAmB to have an economic advantage. The main study result was also insensitive to variations in hospitalization costs, including those attributable to ICU care. Baseline cost difference was also not sensitive to the estimations made by the expert panel. It was not sensitive to the dose of LAmB when given as an alternative, or to the LAmB given in combination with posaconazole as an alternative. Replacing 3 mg/kg/day doses with 5 mg/kg/day doses for alternative LAmB did not affect the cost advantage of caspofungin. The sensitivity to the time spent in the ICU, tested within a range of 1 -10 days, was negligible. A similar outcome was observed with excluding the use of concurrent antibiotics and G-CSF, and the costs of screening and monitoring tests, as well as with switching all intravenous doses of the alternative voriconazole to oral voriconazole and vice versa.
One-and two-way exchanges in probability data, between the caspofungin and LAmB arms in the decision tree, did not impact the cost differential. A similar outcome resulted when the LAmB probability data were replaced with empirical LAmB data reported elsewhere in the literature. 14 According to the uncertainty analysis, main clinical variables, as per the ranking of their impact on the model outcome, are demonstrated in Figure 3 . Based on the 'cost saving' probability distribution, resulting from the Monte Carlo simulation, the mean cost saving was AU$7247 per patient in favour of caspofungin. There was a 99.8% chance that caspofungin would be associated with a cost saving over LAmB. The maximum expected cost saving with caspofungin was AU$16 354, while the maximum expected cost saving with LAmB was AU$1583. A 'cost saving' probability curve is shown in Figure 4 .
Discussion
This economic investigation is the first to focus on the role of caspofungin as empirical therapy from an Australian perspective. Caspofungin was evaluated in comparison with LAmB, the standard empirical antifungal therapy as per the current Australian guidelines. 6, 7 Caspofungin demonstrated a cost saving over LAmB (AU$7245 difference, Table 6 ). Importantly, because caspofungin was associated with a higher efficacy (i.e. higher success rate and lower death rate) as well as lower cost per success and death prevented (in the order of AU$24169 and AU$7270, respectively), it appears to be a dominant empirical antifungal treatment over LAmB. Therefore, in terms of the overall economic evaluation, the incremental cost-effectiveness ratio would not be as good an indicator as the total difference in medication costs.
As there were no long-term-survival and quality-of-life data available from Walsh et al., 5 it was not possible for the present analysis to estimate the life years gained 16 as well as to apply the Markov modelling. 17 Moreover, long-term data are more relevant to studies adopting a healthcare system or societal perspective, while the hospital perspective is more appropriate for acute diseases such as febrile neutropenia.
An ideal economic evaluation would be based on the best available clinical evidence, whereby a double-blinded randomized clinical trial would be the most valid and reliable source of data. 18 -20 Importantly, the economic results of the current study are applicable to the Australian setting, as the results from the trial by Walsh et al. 5 are generalizable to the Australian healthcare setting. The trial was an international multicentre study, the patients reflected the normal Australian clinical caseload and the administration of both caspofungin and LAmB is similarly recommended in current Australian guidelines. 6, 7 A major strength of the current model is that all patients were followed up, even after discontinuing randomized therapy. In addition, the decision model considered all possible clinical patterns reported in the Walsh et al. study. 5 In a recent Germanybased economic evaluation, 21 caspofungin was demonstrated to be at least cost-neutral compared with LAmB for empirical use. Nonetheless, as per the study objective and design, costs presented were based on the nephrotoxicity outcome alone, and thus, were not directly comparable to the current study. Two recent studies, one from Italy 22 and the other from the UK, 23 aimed to compare the overall costs (combined acquisition and secondary costs) of caspofungin and LAmB for neutropenia with fever. Both evaluations, based on the same model, extracted data from the Walsh et al. 5 trial, and revealed a lower cost associated with caspofungin. These studies, however, did not consider the cost consequences associated with lack of efficacy, persistence of fever and breakthrough fungal infections. This is the only caspofungin economic study in which measured costs fully reflected the standard five component endpoint currently used in assessing the efficacy of empirical antifungal therapy. 24 This approach is critical for the accurate depiction of the overall cost of treatment. Including some treatment pathways while excluding others may lead to inaccurate estimation of costs. Importantly, the Italy-and UK-based studies assumed that patients who discontinued caspofungin were switched to LAmB only, and that patients who discontinued LAmB were switched to caspofungin only. These are impractical, given the availability of cheaper and effective antifungals (i.e. voriconazole and posaconazole) in actual practice, and will lead to unrealistic secondary costs and, ultimately, actual overall medications costs. The current evaluation, on the other hand, is unique as the estimation of alternatives considered the site of infections as well as the type of causative fungi. The estimations by the expert panel were based on day-to-day clinical experience, which reflected current Australian practice and provided more realistic cost estimates. A better understanding of the full impact of therapies was also enabled. According to the expert panel, no patients with baseline infections failed therapy because of death. This was due to the small number of patients with baseline infections who did not respond to therapy (13 and 20 patients for caspofungin and LAmB, respectively). 5 While caspofungin had lower treatment-related toxicity, better success with patients with baseline fungal infections and a higher rate of survival after the end of therapy, LAmB was associated with fewer breakthrough fungal infections and higher rate of resolution of fever. However, the total monetary values of these outcomes (i.e. secondary/alternatives costs) were similar between the two medications (Figure 2) , mainly because the overall failure rates were similar between the antifungals (Table 1) , and the alternatives given after failures comprised similarly cheaper voriconazole or posaconazole ( Table 2 ). The cost associated with the use of LAmB as an alternative to caspofungin was more than that associated with the caspofungin use as an alternative to LAmB, and hence, LAmB was associated with the lower cost of the alternative therapy, but only slightly (AU$7730 versus AU$8442) (Figure 2) . Therefore, the observed net cost difference was almost totally due to the difference in the initial antifungal treatment costs; the lower acquisition cost of caspofungin (AU$13 622) relative to LAmB (AU$22 804) (Figure 2 ). These observations highlight the need for decision-makers to consider both acquisition costs and secondary costs (cost of therapy failure), when deciding on the prescribing of a medication.
The cost of treating common side effects (e.g. chills and rash) was not included in the current study. It was not possible for the expert panel to provide reliable estimations for the resources used to manage such side effects. However, these side effects are usually moderate and do not cause discontinuations of therapy; in addition, they are not likely to affect cost estimations.
The sensitivity analyses conducted on the dataset demonstrated that the overall difference in cost was only sensitive to the duration of antifungal therapy. This is expected as, for both antifungals, 1 day accounts for almost 8% of the total therapy cost. LAmB had the economic advantage when the mean duration of its administration was ,10.9 days. This is important given that two previous studies 14, 25 on empirical LAmB, which also used the five component endpoint to assess outcomes, reported LAmB treatment durations of 10.8 days (mean) and 7 days (median), respectively. The cost advantage of caspofungin was robust enough that it was not sensitive to realistic variations in antifungal prices or hospitalization costs. Regarding the ICU cost per day, from the Australian perspective, no exclusive cost per bed was available, and thus, the average total hospitalization cost per day was used instead. In any case, when cost per day during the ICU stay was replaced with a total ICU daily cost (AU$2996) reported in the literature for a local hospital, 26 the net difference in cost did not change. Importantly, the main result was not sensitive to the estimations by the expert panel. Similarly, the difference in the overall probability of distribution for variables between both arms of the study appears not to be a key factor behind any cost differentials measured between the two antifungals, as the switches made in the overall probability of distribution did not affect the study conclusion.
According to the uncertainty analysis, the variables that affected the model most were fever without baseline infections, persistent fever and therapeutic failure of fever without baseline infections ( Figure 3 ). This is expected, as these variables have the highest ratios of patient distribution among all variables, which translates into longer overall hospital stay and, ultimately, higher overall cost. Importantly, the Monte Carlo simulation demonstrated a clear economic advantage with using caspofungin. The probability of caspofungin generating cost savings over LAmB was very high. Out of 10000 simulations, the mean net saving was associated with caspofungin. The maximum expected cost saving was higher with caspofungin than with LAmB ( Figure 4) .
The use of an expert panel to estimate data is recognized as a limitation in the current study. Hospital resources used in patient management could have been driven from local hospital protocols. For the purpose of this study however, the expert panel, representing a wide variety of hospital practices, was used to increase the generalizability of results to patients outside the local hospital setting. As no literature regarding the use of empirical antifungals as alternatives is available, the expert panel provided data regarding alternatives given after discontinuations. Expert judgement is often referred to as the best available source in situations where no other data sources are available. 27 The number of panel members involved was in accordance with the literature. 28 -30 It is a limitation that the decision tree structure only allowed for a single switch to alternatives after failures. Nevertheless, the two model arms were similar in terms of failure ratio (Table 1) and in the most commonly used alternative ( Table 2 ). The assumption that the duration of subsequent alternative medication was similar to that of the discontinued initial medication is another limitation. No data are available regarding the duration of empirical therapy in Australia. However, according to the expert panel, the duration appears to be similar for different antifungal empirical agents if used in similar settings, which is consistent with the results in the literature on empirical antifungals. 5, 14, 25 All assumptions were validated by the panel before they were applied. Future investigations that prospectively collect economic data of empirical therapies will be valuable, and will address the limitations in the current study.
The decision regarding the best antifungal for empirical use is mostly based on available efficacy and safety data. However, cost considerations remain critically important, especially since increasing demand for high-cost antifungals (e.g. LAmB, caspofungin and voriconazole) is exerting a significant strain on limited hospital budgets. 31, 32 A recent Australia-based economic evaluation has established the role of voriconazole as compared with the antifungal of choice (i.e. LAmB) for empirical use in Australia. 28 This work helps to establish the role of caspofungin in the same setting. Importantly, the value of the current study extends beyond the reporting of economics. The analysis has provided an outline to anticipate costs associated with empirical regimens of caspofungin and LAmB as per local practices and patterns (e.g. therapy duration and alternative medications).
In conclusion, caspofungin appears to be a more costbeneficial empirical therapy than LAmB in febrile neutropenia, as it displayed higher efficacy and was associated with lower direct medical costs. The findings of the present study suggest that current Australian guidelines may need to be reviewed, as these recommend LAmB as the first choice for empirical therapy. 
